Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. 14 lis 2023 · Salmonella Vaccine Study in Oxford is a first-in-human study of a novel vaccine against invasive non-typhoidal Salmonellosis (iNTS), a neglected disease largely affecting low- and middle-income countries.

  2. 14 lis 2023 · Method and analysis: The Salmonella Vaccine Study in Oxford is a randomised placebo-controlled participant-observer blind phase I study of the iNTS-GMMA vaccine.

  3. 14 lis 2023 · Here, a first-in-human study of a novel vaccine (iNTS-GMMA) containing S. Typhimurium and S. Enteritidis Generalised Modules for Membrane Antigens (GMMA) outer membrane vesicles is presented. METHOD AND ANALYSIS: The Salmonella Vaccine Study in Oxford is a randomised placebo-controlled participant-observer blind phase I study of the iNTS-GMMA ...

  4. 14 cze 2017 · Finally, new candidate antigens and their relevance in the refined design of anti- Salmonella vaccines are discussed, along with antigen vectorization strategies such as nanoparticles or secretory immunoglobulins, with a focus on potentiating mucosal vaccine efficacy. KEYWORDS: Salmonella, immunity, vaccination, gastrointestinal mucosa. Go to:

  5. 23 maj 2023 · Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteers.

  6. In this review we focus on (1) recent advances in live attenuated Salmonella vaccine development, (2) improvements in expression of foreign antigens in carrier vaccines and (3) adaptation of attenuated strains as sources of purified antigens and vesicles that can be used for subunit and conjugate vaccines or together with attenuated vaccine ...

  7. www.hra.nhs.uk › research-summaries › salmonella-vaccine-study-in-oxford-salvoSalmonella Vaccine Study in Oxford (SALVO)

    This study is a first-in-human clinical trial involving 30-42 healthy adult participants who will be randomly allocated to receive either iNTS-GMMA or a placebo. The main objective of this trial is to evaluate the safety of the iNTS-GMMA vaccine in healthy adults in the UK.

  1. Ludzie szukają również